Shkreli, 34, is charged with eight counts of securities fraud and conspiracy to commit both securities and wire fraud.
Shkreli, who has pleaded not guilty in the case, spent much of Monday in the cafeteria sitting quietly at a table, sometimes with his father and other supporters.
Meanwhile, Shkreli’s lawyers and prosecutors sat patiently in Matsumoto’s courtroom.
Prosecutors say Shkreli defrauded more than a half-dozen people who invested in two hedge funds he ran by lying about his investing prowess, and by misstating the size, performance and strategy of the funds.
Prosecutors also say that after Shkreli lost most of their money or used it secretly to capitalize his new drug company, he then looted that company, Retrophin, out of stocks and cash to pay back the investors.
Shkreli denies the charges, which are unrelated to the public outrage he sparked in 2015 by hiking the price of the anti-parasite drug Daraprim by more than 5,000 percent while running another drug company, Turing Pharmaceuticals.
The trial began in late June.